questionsmedicales.fr
Eucaryotes
Viridiplantae
Streptophyta
Embryophyta
Tracheobionta
Magnoliopsida
Boraginaceae
Boraginaceae : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Plantes médicinales
Botanique
Essais cliniques
Phytothérapie
Identification botanique
Phytothérapie
Classification des plantes
Botanique
Outils de diagnostic
Botanique
Symptômes
5
Réactions allergiques
Effets secondaires
Effets indésirables
Phytothérapie
Allergies
Réactions cutanées
Troubles respiratoires
Allergies
Prévention
5
Prévention
Effets indésirables
Précautions
Consultation médicale
Interactions médicamenteuses
Phytothérapie
Stockage
Préparations médicinales
Recommandations
Phytothérapie
Traitements
5
Médecine traditionnelle
Phytothérapie
Remèdes naturels
Phytothérapie
Inflammation
Efficacité thérapeutique
Préparation de remèdes
Phytothérapie
Contre-indications
Phytothérapie
Complications
5
Réaction allergique
Consultation médicale
Maladies préexistantes
Complications
Facteurs de risque
5
Allergies
Facteurs de risque
Intoxication
Facteurs de risque
Personnes âgées
Vulnérabilité
Maladies chroniques
Précautions
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Boraginaceae : Questions médicales les plus fréquentes",
"headline": "Boraginaceae : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Boraginaceae : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-13",
"dateModified": "2025-04-08",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Boraginaceae"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Magnoliopsida",
"url": "https://questionsmedicales.fr/mesh/D019684",
"about": {
"@type": "MedicalCondition",
"name": "Magnoliopsida",
"code": {
"@type": "MedicalCode",
"code": "D019684",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B01.875.800.575.912.250"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Amsinckia",
"alternateName": "Amsinckia",
"url": "https://questionsmedicales.fr/mesh/D029682",
"about": {
"@type": "MedicalCondition",
"name": "Amsinckia",
"code": {
"@type": "MedicalCode",
"code": "D029682",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B01.875.800.575.912.250.150.122"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Borago",
"alternateName": "Borago",
"url": "https://questionsmedicales.fr/mesh/D029683",
"about": {
"@type": "MedicalCondition",
"name": "Borago",
"code": {
"@type": "MedicalCode",
"code": "D029683",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B01.875.800.575.912.250.150.188"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Consoude",
"alternateName": "Comfrey",
"url": "https://questionsmedicales.fr/mesh/D020844",
"about": {
"@type": "MedicalCondition",
"name": "Consoude",
"code": {
"@type": "MedicalCode",
"code": "D020844",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B01.875.800.575.912.250.150.210"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Cordia",
"alternateName": "Cordia",
"url": "https://questionsmedicales.fr/mesh/D031213",
"about": {
"@type": "MedicalCondition",
"name": "Cordia",
"code": {
"@type": "MedicalCode",
"code": "D031213",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B01.875.800.575.912.250.150.327"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Echium",
"alternateName": "Echium",
"url": "https://questionsmedicales.fr/mesh/D036661",
"about": {
"@type": "MedicalCondition",
"name": "Echium",
"code": {
"@type": "MedicalCode",
"code": "D036661",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B01.875.800.575.912.250.150.385"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Eriodictyon",
"alternateName": "Eriodictyon",
"url": "https://questionsmedicales.fr/mesh/D031322",
"about": {
"@type": "MedicalCondition",
"name": "Eriodictyon",
"code": {
"@type": "MedicalCode",
"code": "D031322",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B01.875.800.575.912.250.150.415"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Heliotropium",
"alternateName": "Heliotropium",
"url": "https://questionsmedicales.fr/mesh/D028162",
"about": {
"@type": "MedicalCondition",
"name": "Heliotropium",
"code": {
"@type": "MedicalCode",
"code": "D028162",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B01.875.800.575.912.250.150.444"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Lithospermum",
"alternateName": "Lithospermum",
"url": "https://questionsmedicales.fr/mesh/D029684",
"about": {
"@type": "MedicalCondition",
"name": "Lithospermum",
"code": {
"@type": "MedicalCode",
"code": "D029684",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B01.875.800.575.912.250.150.501"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Pulmonaria",
"alternateName": "Pulmonaria",
"url": "https://questionsmedicales.fr/mesh/D029685",
"about": {
"@type": "MedicalCondition",
"name": "Pulmonaria",
"code": {
"@type": "MedicalCode",
"code": "D029685",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B01.875.800.575.912.250.150.750"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Boraginaceae",
"alternateName": "Boraginaceae",
"code": {
"@type": "MedicalCode",
"code": "D028082",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Maryam Noroozi",
"url": "https://questionsmedicales.fr/author/Maryam%20Noroozi",
"affiliation": {
"@type": "Organization",
"name": "Department of Ecology & Evolutionary Biology, University of Tennessee, Knoxville, TN, 37996, USA."
}
},
{
"@type": "Person",
"name": "Farrokh Ghahremaninejad",
"url": "https://questionsmedicales.fr/author/Farrokh%20Ghahremaninejad",
"affiliation": {
"@type": "Organization",
"name": "Department of Plant Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, 15719-14911, Iran. fgh@khu.ac.ir."
}
},
{
"@type": "Person",
"name": "Mehrshid Riahi",
"url": "https://questionsmedicales.fr/author/Mehrshid%20Riahi",
"affiliation": {
"@type": "Organization",
"name": "Department of Plant Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, 15719-14911, Iran."
}
},
{
"@type": "Person",
"name": "James I Cohen",
"url": "https://questionsmedicales.fr/author/James%20I%20Cohen",
"affiliation": {
"@type": "Organization",
"name": "Department of Botany and Plant Ecology, Weber State University, 1415 Edvalson St., Dept. 2504, Ogden, UT, 84408, USA."
}
},
{
"@type": "Person",
"name": "José Luis Guil-Guerrero",
"url": "https://questionsmedicales.fr/author/Jos%C3%A9%20Luis%20Guil-Guerrero",
"affiliation": {
"@type": "Organization",
"name": "Food Technology Division, University of Almería, 04120, Almería, Spain."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma.",
"datePublished": "2023-03-11",
"url": "https://questionsmedicales.fr/article/37018924",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejca.2023.03.006"
}
},
{
"@type": "ScholarlyArticle",
"name": "Adverse Events Induced by Nivolumab Plus Ipilimumab",
"datePublished": "2022-08-14",
"url": "https://questionsmedicales.fr/article/35916661",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/07357907.2022.2108827"
}
},
{
"@type": "ScholarlyArticle",
"name": "Nivolumab plus ipilimumab in malignant pleural mesothelioma.",
"datePublished": "2022-07-25",
"url": "https://questionsmedicales.fr/article/35835722",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/14737140.2022.2102482"
}
},
{
"@type": "ScholarlyArticle",
"name": "Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma.",
"datePublished": "2023-12-14",
"url": "https://questionsmedicales.fr/article/38104353",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.lungcan.2023.107440"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pseudo-Progression of Melanoma Treated with Nivolumab/Ipilimumab: A Case Report.",
"datePublished": "2023-08-07",
"url": "https://questionsmedicales.fr/article/37545116",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.12659/AJCR.940954"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Eucaryotes",
"item": "https://questionsmedicales.fr/mesh/D056890"
},
{
"@type": "ListItem",
"position": 3,
"name": "Viridiplantae",
"item": "https://questionsmedicales.fr/mesh/D057948"
},
{
"@type": "ListItem",
"position": 4,
"name": "Streptophyta",
"item": "https://questionsmedicales.fr/mesh/D057949"
},
{
"@type": "ListItem",
"position": 5,
"name": "Embryophyta",
"item": "https://questionsmedicales.fr/mesh/D019669"
},
{
"@type": "ListItem",
"position": 6,
"name": "Tracheobionta",
"item": "https://questionsmedicales.fr/mesh/D064028"
},
{
"@type": "ListItem",
"position": 7,
"name": "Magnoliopsida",
"item": "https://questionsmedicales.fr/mesh/D019684"
},
{
"@type": "ListItem",
"position": 8,
"name": "Boraginaceae",
"item": "https://questionsmedicales.fr/mesh/D028082"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Boraginaceae - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Boraginaceae",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-05",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Boraginaceae",
"description": "Comment identifier les plantes de la famille Boraginaceae ?\nQuels tests pour évaluer l'efficacité des Boraginaceae ?\nY a-t-il des critères spécifiques pour le diagnostic ?\nComment distinguer les Boraginaceae des autres familles ?\nQuels outils pour identifier les Boraginaceae ?",
"url": "https://questionsmedicales.fr/mesh/D028082?mesh_terms=Ipilimumab#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Boraginaceae",
"description": "Quels symptômes sont associés à l'utilisation des Boraginaceae ?\nLes Boraginaceae provoquent-elles des effets indésirables ?\nQuels symptômes d'intoxication peuvent survenir ?\nComment reconnaître une réaction allergique aux Boraginaceae ?\nLes Boraginaceae peuvent-elles causer des troubles respiratoires ?",
"url": "https://questionsmedicales.fr/mesh/D028082?mesh_terms=Ipilimumab#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Boraginaceae",
"description": "Comment éviter les effets indésirables des Boraginaceae ?\nQuelles précautions prendre avant d'utiliser des Boraginaceae ?\nLes Boraginaceae peuvent-elles interagir avec d'autres médicaments ?\nComment stocker les préparations à base de Boraginaceae ?\nY a-t-il des recommandations pour l'utilisation des Boraginaceae ?",
"url": "https://questionsmedicales.fr/mesh/D028082?mesh_terms=Ipilimumab#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Boraginaceae",
"description": "Comment les Boraginaceae sont-elles utilisées en médecine ?\nQuels remèdes à base de Boraginaceae existent ?\nLes Boraginaceae sont-elles efficaces contre l'inflammation ?\nComment préparer un remède à base de Boraginaceae ?\nY a-t-il des contre-indications pour les traitements à base de Boraginaceae ?",
"url": "https://questionsmedicales.fr/mesh/D028082?mesh_terms=Ipilimumab#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Boraginaceae",
"description": "Quelles complications peuvent survenir avec les Boraginaceae ?\nLes Boraginaceae peuvent-elles causer des problèmes hépatiques ?\nComment gérer une réaction allergique aux Boraginaceae ?\nY a-t-il des risques d'intoxication avec les Boraginaceae ?\nLes Boraginaceae peuvent-elles aggraver des maladies existantes ?",
"url": "https://questionsmedicales.fr/mesh/D028082?mesh_terms=Ipilimumab#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Boraginaceae",
"description": "Qui est à risque d'allergies aux Boraginaceae ?\nLes femmes enceintes doivent-elles éviter les Boraginaceae ?\nQuels facteurs augmentent le risque d'intoxication ?\nLes personnes âgées sont-elles plus vulnérables ?\nY a-t-il des risques pour les personnes atteintes de maladies chroniques ?",
"url": "https://questionsmedicales.fr/mesh/D028082?mesh_terms=Ipilimumab#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les plantes de la famille Boraginaceae ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les Boraginaceae se caractérisent par des fleurs en grappes et des feuilles alternées."
}
},
{
"@type": "Question",
"name": "Quels tests pour évaluer l'efficacité des Boraginaceae ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études cliniques et des tests in vitro sont utilisés pour évaluer leur efficacité."
}
},
{
"@type": "Question",
"name": "Y a-t-il des critères spécifiques pour le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'identification botanique et l'analyse des propriétés médicinales."
}
},
{
"@type": "Question",
"name": "Comment distinguer les Boraginaceae des autres familles ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'observation des caractéristiques florales et des feuilles aide à la distinction."
}
},
{
"@type": "Question",
"name": "Quels outils pour identifier les Boraginaceae ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des guides botaniques et des applications de reconnaissance de plantes sont utiles."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés à l'utilisation des Boraginaceae ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des réactions allergiques, des troubles gastro-intestinaux ou des effets secondaires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les Boraginaceae provoquent-elles des effets indésirables ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines espèces peuvent causer des effets indésirables comme des nausées."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'intoxication peuvent survenir ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes tels que des vomissements, des douleurs abdominales peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une réaction allergique aux Boraginaceae ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des démangeaisons, éruptions cutanées ou œdème peuvent indiquer une allergie."
}
},
{
"@type": "Question",
"name": "Les Boraginaceae peuvent-elles causer des troubles respiratoires ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles respiratoires peuvent survenir en cas d'allergie ou d'intoxication."
}
},
{
"@type": "Question",
"name": "Comment éviter les effets indésirables des Boraginaceae ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est conseillé de commencer par de faibles doses et de surveiller les réactions."
}
},
{
"@type": "Question",
"name": "Quelles précautions prendre avant d'utiliser des Boraginaceae ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Consulter un professionnel de santé avant utilisation, surtout en cas de maladies préexistantes."
}
},
{
"@type": "Question",
"name": "Les Boraginaceae peuvent-elles interagir avec d'autres médicaments ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent interagir avec certains médicaments, il est donc important de vérifier."
}
},
{
"@type": "Question",
"name": "Comment stocker les préparations à base de Boraginaceae ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Conserver dans un endroit frais et sec, à l'abri de la lumière pour préserver l'efficacité."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations pour l'utilisation des Boraginaceae ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Suivre les recommandations d'un professionnel de santé et respecter les dosages conseillés."
}
},
{
"@type": "Question",
"name": "Comment les Boraginaceae sont-elles utilisées en médecine ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont utilisées pour traiter des inflammations, des douleurs et des troubles cutanés."
}
},
{
"@type": "Question",
"name": "Quels remèdes à base de Boraginaceae existent ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des infusions, des pommades et des extraits sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Les Boraginaceae sont-elles efficaces contre l'inflammation ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études montrent qu'elles peuvent réduire l'inflammation et la douleur."
}
},
{
"@type": "Question",
"name": "Comment préparer un remède à base de Boraginaceae ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les feuilles peuvent être infusées ou utilisées en cataplasme pour des applications topiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des contre-indications pour les traitements à base de Boraginaceae ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines personnes, comme les femmes enceintes, doivent éviter leur utilisation."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les Boraginaceae ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des allergies sévères ou des troubles gastro-intestinaux peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les Boraginaceae peuvent-elles causer des problèmes hépatiques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines espèces contiennent des composés toxiques pouvant affecter le foie."
}
},
{
"@type": "Question",
"name": "Comment gérer une réaction allergique aux Boraginaceae ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Cesser l'utilisation immédiatement et consulter un médecin si les symptômes persistent."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques d'intoxication avec les Boraginaceae ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une consommation excessive peut entraîner des symptômes d'intoxication."
}
},
{
"@type": "Question",
"name": "Les Boraginaceae peuvent-elles aggraver des maladies existantes ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent aggraver certaines conditions, comme les maladies hépatiques ou rénales."
}
},
{
"@type": "Question",
"name": "Qui est à risque d'allergies aux Boraginaceae ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes ayant des antécédents d'allergies aux plantes sont plus à risque."
}
},
{
"@type": "Question",
"name": "Les femmes enceintes doivent-elles éviter les Boraginaceae ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il est recommandé qu'elles évitent leur utilisation en raison de risques potentiels."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'intoxication ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une consommation excessive ou l'utilisation de préparations non contrôlées augmentent le risque."
}
},
{
"@type": "Question",
"name": "Les personnes âgées sont-elles plus vulnérables ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent être plus sensibles aux effets indésirables des Boraginaceae."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques pour les personnes atteintes de maladies chroniques ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes atteintes de maladies chroniques doivent être prudentes avec leur utilisation."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 08/04/2025
Contenu vérifié selon les dernières recommandations médicales
2 publications dans cette catégorie
Affiliations :
Department of Ecology & Evolutionary Biology, University of Tennessee, Knoxville, TN, 37996, USA.
Department of Plant Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, 15719-14911, Iran.
Publications dans "Boraginaceae" :
2 publications dans cette catégorie
Affiliations :
Department of Plant Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, 15719-14911, Iran. fgh@khu.ac.ir.
Publications dans "Boraginaceae" :
2 publications dans cette catégorie
Affiliations :
Department of Plant Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, 15719-14911, Iran.
Publications dans "Boraginaceae" :
2 publications dans cette catégorie
Affiliations :
Department of Botany and Plant Ecology, Weber State University, 1415 Edvalson St., Dept. 2504, Ogden, UT, 84408, USA.
Publications dans "Boraginaceae" :
2 publications dans cette catégorie
Affiliations :
Food Technology Division, University of Almería, 04120, Almería, Spain.
Publications dans "Boraginaceae" :
2 publications dans cette catégorie
Affiliations :
Food Technology Division, University of Almería, 04120, Almería, Spain.
Publications dans "Boraginaceae" :
2 publications dans cette catégorie
Affiliations :
Food Technology Division, University of Almería, 04120, Almería, Spain.
Publications dans "Boraginaceae" :
2 publications dans cette catégorie
Affiliations :
Institute of Biology, Faculty of Natural Sciences and Mathematics, Ss. Cyril and Methodius University, Skopje, R. N. Macedonia.
Macedonian Academy of Sciences and Arts, Krste Misirkov 2, 1000, Skopje, R. N. Macedonia.
Publications dans "Boraginaceae" :
2 publications dans cette catégorie
Affiliations :
Institute of Chemistry, Faculty of Natural Sciences and Mathematics, Ss. Cyril and Methodius University, Skopje, R. N. Macedonia.
Publications dans "Boraginaceae" :
2 publications dans cette catégorie
Affiliations :
Kutateladze Institute of Pharmacochemistry, Tbilisi State Medical University, 36 P.Sarajishvili Street, 0159 Tbilisi, Georgia.
Publications dans "Boraginaceae" :
2 publications dans cette catégorie
Affiliations :
Kutateladze Institute of Pharmacochemistry, Tbilisi State Medical University, 36 P.Sarajishvili Street, 0159 Tbilisi, Georgia.
Publications dans "Boraginaceae" :
2 publications dans cette catégorie
Affiliations :
Kutateladze Institute of Pharmacochemistry, Tbilisi State Medical University, 36 P.Sarajishvili Street, 0159 Tbilisi, Georgia.
Publications dans "Boraginaceae" :
2 publications dans cette catégorie
Affiliations :
Kutateladze Institute of Pharmacochemistry, Tbilisi State Medical University, 36 P.Sarajishvili Street, 0159 Tbilisi, Georgia.
Publications dans "Boraginaceae" :
2 publications dans cette catégorie
Affiliations :
School of Pharmacy, Aristotle University, 54124 Thessaloniki, Greece.
Publications dans "Boraginaceae" :
1 publication dans cette catégorie
Affiliations :
Grainger Bioinformatics Center, Department of Science and Education, The Field Museum, Chicago, Illinois, USA.
Departamento de Biodiversidad y Conservación, Real Jardín Botánico (RJB-CSIC), Madrid, Spain.
Publications dans "Boraginaceae" :
1 publication dans cette catégorie
Affiliations :
Departamento de Biodiversidad y Conservación, Real Jardín Botánico (RJB-CSIC), Madrid, Spain.
Publications dans "Boraginaceae" :
1 publication dans cette catégorie
Affiliations :
Departamento de Biodiversidad y Conservación, Real Jardín Botánico (RJB-CSIC), Madrid, Spain.
Centro de Investigación en Biodiversidad y Cambio Global (CIBC-UAM), Universidad Autónoma de Madrid, Madrid, Spain.
Departamento de Biología (Botánica), Universidad Autónoma de Madrid, Madrid, Spain.
Publications dans "Boraginaceae" :
1 publication dans cette catégorie
Affiliations :
Centro de Investigación en Biodiversidad y Cambio Global (CIBC-UAM), Universidad Autónoma de Madrid, Madrid, Spain.
Departamento de Biología (Botánica), Universidad Autónoma de Madrid, Madrid, Spain.
Publications dans "Boraginaceae" :
1 publication dans cette catégorie
Affiliations :
Centro de Investigación en Biodiversidad y Cambio Global (CIBC-UAM), Universidad Autónoma de Madrid, Madrid, Spain.
Departamento de Biología (Botánica), Universidad Autónoma de Madrid, Madrid, Spain.
Publications dans "Boraginaceae" :
1 publication dans cette catégorie
Affiliations :
Departamento de Biodiversidad y Conservación, Real Jardín Botánico (RJB-CSIC), Madrid, Spain.
Publications dans "Boraginaceae" :
Differing doses of ipilimumab (IPI) are used in combination with an anti-PD1 antibody in advanced melanoma. There is no data on the outcomes of patients who progress following low-dose IPI (< 3 mg/kg)...
Patients with resected stage III, unresectable stage III or IV melanoma who received low dose IPI (< 3 mg/kg) with an anti-PD1 antibody with recurrence (neo/adjuvant) or progressive disease (metastati...
Total 36 patients received low-dose IPI with an anti-PD1 antibody, 18 (50%) in the neo/adjuvant and 18 (50%) in the metastatic setting. Of which, 20 (56%) had primary resistance and 16 (44%) had acqui...
IPI3 following recurrence/progression on low dose IPI has clinical activity, including in primary resistance. IPI dosing is therefore critical in a subset of patients....
A systematic review and meta-analysis of randomized controlled trials (RCTs) were performed to examine treatment-related adverse events (TRAEs) for combination of nivolumab (NIVO) and ipilimumab (IPI)...
Unresectable pleural mesothelioma is a poor prognosis disease. Improvement in overall survival (OS) has been shown with PEMETREXED combined with CISPLATIN. BEVACIZUMAB combined with chemotherapy is as...
Immune Checkpoint Inhibition (ICI) monotherapy seemed to be promising but is controversial. ICI combination showed significant results. NIVOLUMAB, an anti-Programmed-Death-receptor 1, associated with ...
These results represent a big step in unresectable pleural mesothelioma. The benefit in non-epithelioid subtype is impressive (OS 18.1 months (95%CI 12.2-22.8) vs 8.8 months 95%CI (7.4-10.2) HR 0.46 (...
Nivolumab (anti-PD-1) plus ipilimumab (anti-CTLA-4) is a new first-line treatment combination for patients with pleural mesothelioma. Nivolumab-ipilimumab improved the survival, however, 30.3% of the ...
Clinical data of patients with mesothelioma treated with nivolumab and ipilimumab were prospectively collected. Clinical parameters were obtained every visit, CT scans were evaluated every 12 weeks an...
Between January 2021 and August 2022, 184 patients were treated with nivolumab plus ipilimumab. The median follow-up was 12.1 months (95 %CI 11.1 - 13.1). Grade 3-4 TRAEs were seen in 27.7 % of the pa...
Nivolumab plus ipilimumab had an equal efficacy in a real-world comparable population but also a high risk of TRAE's, leading to discontinuation of treatment in 25% of the patients....
BACKGROUND Melanoma is an aggressive skin cancer that can be difficult to manage. Its treatment has been transformed by immunotherapy. Melanoma cells frequently have mutations that make them vulnerabl...
Limited prospective data are available on sequential immunotherapy and BRAF/MEK inhibition for...
SECOMBIT is a randomized, three-arm, noncomparative phase II trial (ClinicalTrials.gov identifier: NCT02631447). Patients with untreated, metastatic...
A total of 209 patients were randomly assigned (69 in arm A, 71 in arm B, and 69 in arm C). At a median follow-up of 32.2 (interquartile range, 27.9-41.6) months, median OS was not reached in any arm ...
Sequential immunotherapy and targeted therapy provide clinically meaningful survival benefits for patients with...
Combined immune checkpoint inhibitor therapy has been successfully used in the treatment of several malignancies. Adverse effects with the combination therapy may be more severe than the ones seen wit...
We report a unique case of a 59-year-old man of dark skin complexion who underwent treatment with intravenous ipilimumab-nivolumab every 3 weeks for metastatic malignant melanoma. After three cycles o...
Ipilimumab-nivolumab therapy was subsequently discontinued due to grade 3 enterocolitis requiring high-dose steroids and intravenous infliximab. About six months later, imaging studies showed a relaps...
We report a unique case of severe vitiligo and poliosis that involved total body surface area in a Caucasian man with dark complexion, resembling albinism. Further studies are warranted to evaluate th...
Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy, yielding significant antitumor responses across multiple cancer types. Combination ICI therapy with anti-CTLA-4 and anti-P...
Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4-blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in patients with...
In a phase III trial, patients with treatment-naive...
A total of 265 patients were enrolled, with 73 going onto step 2 (27 in arm C and 46 in arm D). The study was stopped early by the independent Data Safety Monitoring Committee because of a clinically ...
Combination nivolumab/ipilimumab followed by BRAF and MEK inhibitor therapy, if necessary, should be the preferred treatment sequence for a large majority of patients....
In the last recent years, the introduction in the clinical setting of treatment combinations having immune checkpoint inhibitors as the backbone has dramatically improved the outcomes of patients suff...